The gluten-free, casein-free (GFCF) diet is heralded by strong anecdotal parental reports to greatly improve and even "cure" symptoms of autism spectrum disorders (ASDs). Yet, to date, little conclusive empirical evidence exists supporting its use. Objective: The purpose of this paper is to provide an overview of the state of the recent evidence regarding the use of GFCF diet for treatment of individuals with ASD. Methods: Five database providers (PubMed, Web of Knowledge, EBSCO, ProQuest, and WorldCat) were used to search 19 databases, yielding a total of 491 articles that were published through February 2015. Peer-reviewed articles published between January 2005 and February 2015 were included for review if study participants were identified as having ASD and if the study investigated the effects of the GFCF diet on ASD behaviors or the relationship between the diet and these behaviors. Results: Evaluation of search results yielded eleven reviews, seven group experimental studies including five randomized controlled trials, five case reports, and four group observational studies published during the last 10 years. These studies represent a marked increase in the number of reported studies as well as increased scientific rigor in investigation of GFCF diets in ASD. Conclusion: While strong empirical support for the GFCF diet in ASD is currently lacking, studies point to the need for identifying subsets of individuals (eg, those with documented gastrointestinal abnormalities) who may be the best responders to the GFCF diet. Identifying these subsets is critically needed to enhance rigor in this research area. Until rigorous research supporting the use of GFCF diet is reported, clinicians should continue to use caution and consider several factors when advising regarding implementation of the GFCF diet for individuals with ASD.
Introduction
Autism, or the broader category of autism spectrum disorder (ASD), continues to pose challenges in determining the most efficacious and effective treatment approaches for managing associated social, communication, behavioral, and developmental symptoms. 1 First described in a 1943 case report by Kanner, 2 interventional approaches for autism have been the subject of a vast number of clinical reports and case studies; less common are rigorous intervention trials. Recently, the thinking about ASD has expanded from a solely psychiatric condition to a multisystem inflammatory disorder that includes systemic inflammation of the gastrointestinal (GI) tract impacting the brain, immune system, and metabolism. 3 One popular treatment for addressing possible systemic inflammation is the gluten-free, casein-free (GFCF) diet, heralded by strong anecdotal parental reports of greatly improved 4 and even "cured" symptoms of ASD, such that the child no longer meets criteria for ASD. 5 The GFCF diet was first identified for use in schizophrenia, 6 where a possible genetic defect may contribute to what has been referred to as a "leaky gut", resulting in an overload of gluten (from wheat) and casein (from dairy). It is posited that this overload causes high peptide levels, which may produce an opioid-type effect that manifests in the behavioral symptoms commonly seen in ASD. 7 Others speculate that many individuals with ASD may have undiagnosed gastric conditions and sensitivities that are caused or aggravated by the ingestion of casein and gluten. This discomfort, or even severe pain in some cases, may result in externalizing behaviors (eg, tantrums, screaming, and aggression) and inattention to tasks due to the distraction because of the pain.
Several systematic reviews [8] [9] [10] [11] [12] [13] [14] of GFCF studies have focused on the few existing intervention studies and reported inconclusive results. [8] [9] [10] [11] [12] [13] [14] However, as Kanner 2 noted in his case report, a thorough review must address case studies as well as reports of clinical trials to produce a "full view of the landscape" of what is currently known about the GFCF diet. Such comprehensiveness is needed to assist families and clinical professionals in making informed decisions about implementing the GFCF diet and can identify specific directions for future research.
The purpose of this paper is to provide an overview of the state of the recent evidence regarding the use of GFCF diet for treatment of individuals with ASD as needed for directing future research and advancing clinical practice recommendations. As such, we reviewed the scientific literature published between January 2005 and February 2015 and have organized our review into four sections: summaries of review articles, group experimental intervention studies including randomized clinical trials, case reports, and group observational studies.
Methods
We began our review with a scoping search of the literature in order to gain a broad overview of the existing relevant literature. Table 1 details our search strategies, which were constructed by the third author, a research librarian. Nineteen databases from five database providers (PubMed, Web of Knowledge, EBSCO, ProQuest, and WorldCat) were searched via subject headings and keywords, with the latter truncated and/or phrase searched to capture various forms of gluten, casein, GFCF diet, autism, ASD, and Asperger's syndrome. Search efforts yielded a total of 491 articles. Removal of duplicates and non-English articles left 290 potential articles, whose titles (and abstracts when needed) were independently screened by two members of the research team. Additional screening was conducted for 1) publication date prior to 2005; 2) publication type, such as commentary, letter to the editor, book chapter, or thesis/dissertation; 3) publication in nonpeer reviewed periodical; 4) main topics unrelated to gluten-or casein-restricted diet; 5) main topics unrelated to ASD; 6) non-ASD research participants; and/or 7) non-English publications. Full texts of the remaining 61 publications were read and sorted by article type (ie, review, experimental, case, group observational). Review articles focusing on GFCF diet in ASD were retained; all remaining articles were read for major focus on use of GFCF diet in ASD. Backward searches of references in the eleven included review articles yielded one additional published abstract, resulting in the 27 publications included in our review. At each step of the article reduction process, two researchers discussed discrepancies in their independent evaluations until consensus was reached; when needed, a third member of the research team assisted with deliberations.
Review articles, intervention studies, case reports, and group observational studies were included if the study participants were identified as having ASD, and the study investigated either the effects of the GFCF diet on ASD behaviors or the relationship between the diet and behaviors of individuals with ASD. All articles included for review were published in peer-reviewed, English-language journals between January 2005 and February 2015. Studies were excluded if they did not focus on GFCF diet in ASD. However, because of the paucity of randomized controlled trials (RCTs) reported in the literature and because of the study's rigor, we chose to include the one double-blind RCT reported via published abstract 15 (no other published abstracts reported on a RCT testing GFCF diets in ASD).
Results Reviews
A total of eleven review articles [8] [9] [10] [11] [12] [13] [14] [16] [17] [18] [19] from ten research groups were included in this review and are summarized in Table 2 . Hereafter, we will refer to these eleven review articles as ten reviews because one review article was written as an addendum 11 of the group's review that was published in the prior year. 10 These authors reviewed a RCT reported in 2010 by Whiteley et al, 20 which was published shortly after the original review was released. Notably, six [12] [13] [14] [17] [18] [19] Nutrition and Dietary Supplements 2015:7 submit your manuscript | www.dovepress.com
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GFCF diet in ASD Published in the last 10 years; english 2/28/15 42 Academic Search Premier (eBSCO) (De "Gluten-free diet" OR De "Casein-free diet" OR ("gluten free diet*" OR "gluten free" OR "casein free diet*" OR "casein-free" OR GFCF OR GFD OR "gluten* and casein-free diet*" OR ((gluten OR casein) AND ("restricted diet*" OR "diet* restriction*"))) AND AB (autis* OR ASD OR ASC OR "autism spectrum disorder*" OR "autism spectrum condition*") OR Ti (autis* OR ASD OR ASC OR "autism spectrum disorder*" OR "autism spectrum condition*") Scholarly (peer-reviewed journals)
3/17/15 43 CiNAHL (eBSCO) (MH "Autistic Disorder" OR MH "Asperger Syndrome" OR autis* OR ASD OR ASC OR Asperger*) AND MH "Diet, Gluten-Free" OR GFD OR ((MH "Diet" OR "diet* restriction*" OR "restricted diet*" OR "limited diet*" OR "diet* limit*") AND ("gluten free" OR gluten OR casein OR "casein free" OR GFCF)) (Hw wilson on eBSCO) GFD OR ((gluten OR "gluten free" OR "gluten-free" OR casein OR "casein free" OR "casein-free" OR GFCF) AND (diet* OR "diet* restriction*" OR "restricted diet*" OR "limited diet*" OR "diet* limit*")) AND (De "Autism spectrum disorders" OR De "Asperger's syndrome" OR De "Autism" OR De "Autism spectrum disorders in OR ((gluten OR "gluten free" OR casein OR "casein free" OR GFCF) AND (diet* OR "diet* limit*" OR "limited diet*" OR "diet* restriction*" OR "restricted diet*")))
Peer-reviewed academic journals or reviews, 1997-2014 PsyciNFO (eBSCO) (De "Aspergers Syndrome" OR De "Autism" OR "autism spectrum disorder*" OR "autism spectrum condition*" OR ASD OR ASC OR autis*) AND ((De "Dietary Restraint" OR De "Diets" OR "diet* restriction*" OR "restricted diet*" OR "diet* limitation*" OR "limited diet*") AND (gluten OR casein OR GFCF OR GFD OR "gluten-free" OR "casein free")) Academic journals, books, and dissertations 3/18/15 35 SportDiscus (eBSCO) (De "Casein-free diet" OR De "Gluten-free diet" OR (De "Diet in disease" OR De "Diet therapy" OR De Nutritionally induced diseases" OR De "Diet" OR "diet* restriction*" OR "restricted diet*" OR "diet* limitation*"
OR "limited diet*) AND (De "Gluten-free foods" OR gluten OR "gluten free" OR casein OR "casein free") AND (Asperger* OR ASD OR ASC OR autis* OR "autism spectrum disorder*" OR "autism spectrum condition*") Academic journals, 2002-2014 3/18/15 8 web of Science (web of Knowledge) ("gluten* and casein-free diet*" OR (("gluten free" OR "casein free" OR GFCF OR gluten OR casein) AND ("restricted diet*" OR "diet* restriction*" OR "limited diet*" OR "diet* limit*"))) AND TOPiC: (autis* OR ASD OR ASC OR "autism spectrum disorder*" OR Asperger*) Abbreviations: AB, 2 phase study where A phase is the baseline phase and B phase is the intervention phase; ASD, autism spectrum disorder; GF, gluten-free only; GFCF, gluten-free, casein-free; eBP, evidence-based practice;
Gi, gastrointestinal; RCT, randomized controlled trial.
of the ten reviews were published during the last 2 years of our review period; of these six reviews, five 13, 14, [17] [18] [19] reported on multidimensional considerations (eg, safety, adherence to evidence-based practice standards, diet allergies), informing the use of GFCF diets in the treatment of ASD. Of the ten reviews, two 9, 12 limited their review to RCTs. remaining reviews included uncontrolled studies, group descriptive/observational studies, and case reports in addition to RCTs. The most rigorous review of the GFCF diet in ASD is a 2008 Cochrane Review by Millward et al. 9 They identified only two small RCTs (n=35), which rendered a meta-analysis impossible. The authors concluded that despite the evidence of high use of this diet as well as other complementary and alternative medicines, insufficient evidence exists to support its efficacy. The review of GFCF diet studies conducted by Mulloy et al 10 
Group experimental studies
A total of seven group experimental studies 4, 15, [20] [21] [22] [23] [24] testing the effect of GFCF diet in ASD were included for review, of which six were prospective studies 4,15,20-23 and one 24 a retrospective analysis of data from one 4 of the six prospective studies. Of the six prospective studies, two were double-blind RCTs. 4, 15 Two studies 20,21 used a single-blind RCT design in which the parents provided the child's food, while study personnel supported them with dietary guidance. Two studies 22, 23 used an uncontrolled design to investigate the effect of GF-only, CF-only, and GFCF diet conditions (three separate interventions) on children's behaviors using non-blinded assessments of specific behaviors in the three intervention groups. Of the group experimental studies included for review, only two 15,21 restricted the age span of participants to an age range spanning #2 years; the remaining studies allowed study sample age ranges of up to 18 years. Additionally, only one study 20 tested an intervention that lasted longer than 3 months. Notably, this was the only study that reported statistically significant improvements in the GFCF diet group using blinded assessment. No other studies using blinded assessment found group differences for the GFCF diet. However, one study 4 did note positive anecdotal reports for some participants on the GFCF diet. Table 3 summarizes the seven group experimental studies included in our review.
Case reports
A total of five case reports 5,25-28 were reviewed and are summarized in Table 4 . Of these five cases, one employed a quasi-experimental design. Irvin 25 utilized a ABAB (2-phase design where A1 is the baseline, B1 is the introduction of intervention, A2 is the withdrawal of intervention, and B2 is the reintroduction of intervention) reversal design and measured the frequency of problem behaviors in a controlled setting while on and off the GFCF diet. No significant reduction in problem behaviors was found while the child was on the GFCF diet as compared to a regular diet. However, the remaining four case reports described positive changes in cognitive, behavioral, and language symptoms of the children with ASD following implementation of the GFCF diet. Additionally, in these four cases, 5 child. Three 5, 26, 27 of the five case reports noted that the GFCF diet improved the child's communication skills and cognitive scores so drastically that the children eventually no longer met the diagnostic criteria for ASD. Most notable among the five case reports reviewed was the presence of preexisting GI symptoms in the four cases, 5, [26] [27] [28] reporting improvement in ASD-related symptoms after the implementation of the GFCF diet.
Group observational studies
Four group observational studies [29] [30] [31] [32] were reviewed that contribute evidence informing more nuanced aspects of future GFCF diet trials; these studies are summarized in Table 5 . An observational study by Patel and Curtis 29 incorporated pre-and posttesting of ten children who received a comprehensive, multifaceted treatment regime, which for some children included a GFCF diet. These authors reported improved behavioral, social, motor, and GI symptoms after 3-6 months. In a survey of 293 parents of children with ASD on a GFCF diet, Pennesi and Klein 30 found greatest improvements in the subgroups of children with GI symptoms, allergy symptoms, and those on the GFCF diet for longer than 6 months. In a post hoc analysis of the ScanBrit trial data, Pedersen et al 31 reported that children with the strongest probability of being a responder to GFCF diet after 12 months were those aged 7-9 years, who had clinically significant attention deficit hyperactivity disorder -IV (ADHD-IV) scores.
Discussion
Our review of the recent literature on gluten-and/or caseinrestricted diets for the treatment of ASD yielded eleven reviews, seven group experimental studies, including five RCTs, five case reports, and four group observational studies published during the last 10 years (January 2005 through February 2015). As previously mentioned, the earliest reports within the literature on gluten-and/or casein-restricted diets in ASD have been case studies, with gradual movement toward more rigorous research over the last 10 years. Perhaps this review's strongest contribution to the literature informing GFCF dietary interventions in ASD is the contextual overview of the scientific literature published during the past 10 years. Of the reviews included in our study, the review conducted by Marí-Bauset et al 14 included the largest number of primary (nonreview) studies informing on the effect of gluten-and/or casein-restricted diets in the treatment of individuals with ASD (n=24). Of its 24 relevant studies, 4 (16%) were published in the 1970s, 10 (42%) were published .
Description: exploration of potential explanatory variables for predicting GFCF diet responder status.
ADHD-iv total baseline score, vABS total baseline standard score, ADOS total baseline raw score, age at baseline, laboratory status, continued use of GFCF diet poststudy completion, parent evaluation of effect of dietary intervention.
Statistically significant regression analyses indicate children, aged 7-9 years, who have clinically significant ADHD-IV scores at baseline have strongest probability of benefiting from GFCF diet.
Abbreviations: ADHD, attention deficit hyperactivity disorder; ADHD-IV, ADHD rating scale IV; ADOS, Autism Diagnostic Observation Schedule; AS, Asperger's syndrome; ASD, autism spectrum disorder; CARS, in the 12-year span of 1990 and 2002, and the remaining 10 studies (42%) were published during the 7-year period of 2005 through 2012. This observation, in conjunction with the number of reviews focusing on GFCF in ASD published in 2012 and 2013 (six of ten included in our review) indicates an increased interest in GFCF treatments for ASD over the past 10 years. Researchers' collective understanding of the questions at hand has refined to reflect an incomplete but multifaceted understanding of gluten-and/or caseinrestricted diets in the treatment of ASD. Some studies point to a child's age at diet introduction, 31 while others suggest duration of diet 20, 30 as well as possible food sensitivities and allergies [10] [11] [12] 14, 18 as potential factors impacting efficacy of GFCF diet in ASD. Others note physiological abnormalities in ASD that may help to elucidate potential responders. [33] [34] [35] [36] [37] These findings are highly significant and similar to our conclusions about the state of the science related to the GFCF intervention in ASD.
Limitations
Findings were limited by our specific question investigating the current state of evidence regarding the use of the GFCF dietary intervention in ASD. That is, we were seeking information about results of the GFCF diet itself and not necessarily what patient characteristics might suggest the best responders. As a result, only eight studies included for review contributed evidence as to who may be the best responders to a GFCF diet for treatment of ASD. [10] [11] [12] 14, 18, 20, 30, 31 Future direction: targeting subgroups of likely responders
The recent literature indicates a need for future GFCF diet trials to target likely responders. Case report descriptions of positive effects in the four (of five) cases included in our study reporting GI symptoms are consistent with conclusions drawn from reviews published between January 2005 and February 2015. Specifically, Mulloy et al 10, 11 and Marí-Bauset et al 14 recommended consideration of the GFCF diet only when food allergy and/or sensitivities have been diagnosed. In their reviews of the scientific literature, Dosman et al, 18 Hurwitz, 12 and Mari-Bauset et al 14 recommended screening for celiac disease and/or food allergies prior to implementation of the GFCF diet. Conclusions drawn in at least two reviews, 13, 17 analysis of two clinical trials, 15, 20 and one observational cross-sectional study 30 suggest the existence of a subgroup of responders to GFCF dietary interventions. Empirically derived information suggestive of subgroups that may be responsive to GFCF dietary interventions has only recently come to light and has not yet been incorporated into the published clinical trials included in our review.
Summary
Despite its lack of empirical validation, there is enough interest in the GFCF diet that the treatment strategy remains widely used with individuals with ASD. The GFCF diet serves as a strong exemplar of science lagging behind in its ability to inform the practices of a community of interest. Some reasons for this paucity of empirical support are discussed in the reviewed literature and include challenges related to conducting clinical trials that must ensure dietary compliance and experimental blinding in naturalistic, day-to-day settings and interactions. In short, well-controlled GFCF dietary trials are difficult to conduct but remain desperately needed in order to inform clinical treatment decisions. Further concerted efforts must be made to identify subsets of individuals (eg, those with documented GI abnormalities) who may be the best GFCF diet "responders". Finally, until such evidence is available, clinicians should advise those wishing to implement the GFCF diet that it is not likely to be a "miraculous cure" as some claim. As such, clinicians should use caution and consider a number of factors, such as the individual's overall nutritional status as well as potential added family burden related to cost and time commitments, when advising regarding implementation of the GFCF diet for individuals with ASD. For personal use only.
